Trial Profile
An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Ilodecakin (Primary)
- Indications Breast cancer; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 27 Feb 2020 Status changed from suspended to completed.
- 25 Jun 2018 Status changed from recruiting to suspended.
- 19 Jun 2018 New trial record